-
1
-
-
33644775686
-
Targeting multidrug resistance in cancer
-
Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5:219-34.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 219-234
-
-
Szakacs, G.1
Paterson, J.K.2
Ludwig, J.A.3
Booth-Genthe, C.4
Gottesman, M.M.5
-
2
-
-
53849096994
-
An overview of cancer multidrug resistance: A still unsolved problem
-
Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008;65:3145-67.
-
(2008)
Cell Mol Life Sci
, vol.65
, pp. 3145-3167
-
-
Lage, H.1
-
4
-
-
0036924112
-
Irinotecan: Mechanisms of tumor resistance and novel strategies for modulating its activities
-
Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activities. Ann Oncol 2002;13: 1841-51.
-
(2002)
Ann Oncol
, vol.13
, pp. 1841-1851
-
-
Xu, Y.1
Villalona-Calero, M.A.2
-
5
-
-
0023948518
-
Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: A phase I/II trial
-
Miller RL, Bukowski RM, Budd GT, Purvis J, Weick JK, Sheppard K, et al. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J Clin Oncol 1988;6:880-8.
-
(1988)
J Clin Oncol
, vol.6
, pp. 880-888
-
-
Miller, R.L.1
Bukowski, R.M.2
Budd, G.T.3
Purvis, J.4
Weick, J.K.5
Sheppard, K.6
-
7
-
-
0345256652
-
Cisplatin: Mode of cytotoxic action and molecular basis of resistance
-
Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
-
(2003)
Oncogene
, vol.22
, pp. 7265-7279
-
-
Siddik, Z.H.1
-
8
-
-
34248338806
-
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy
-
Walter RB, Gooley TA, van der Verden VHJ, Loken MR, van Dongen JJM, Flowers DA, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007;109:4168-70.
-
(2007)
Blood
, vol.109
, pp. 4168-4170
-
-
Walter, R.B.1
Gooley, T.A.2
Van Der Verden, V.H.J.3
Loken, M.R.4
Van Dongen, J.J.M.5
Flowers, D.A.6
-
9
-
-
66949176946
-
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: Analysis in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma
-
Takeshita A, Shinjo K, Yamakage N, Ono T, Hirano I, Matsui H, et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analysis in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol 2009;146:34-43.
-
(2009)
Br J Haematol
, vol.146
, pp. 34-43
-
-
Takeshita, A.1
Shinjo, K.2
Yamakage, N.3
Ono, T.4
Hirano, I.5
Matsui, H.6
-
10
-
-
84923082324
-
Drug resistance in cancer: An overview
-
Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers 2014;6:1769-92.
-
(2014)
Cancers
, vol.6
, pp. 1769-1792
-
-
Housman, G.1
Byler, S.2
Heerboth, S.3
Lapinska, K.4
Longacre, M.5
Snyder, N.6
-
11
-
-
0036364467
-
Multidrug resistance in cancer: Role of ATP-dependent transporters
-
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 48-58
-
-
Gottesman, M.M.1
Fojo, T.2
Bates, S.E.3
-
12
-
-
65549121495
-
Human ATP-binding cassette (ABC) transporter family
-
Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics 2009;3:281-90.
-
(2009)
Hum Genomics
, vol.3
, pp. 281-290
-
-
Vasiliou, V.1
Vasiliou, K.2
Nebert, D.W.3
-
14
-
-
84910027197
-
Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter
-
Cole SPC. Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter. J Biol Chem 2014;289:30880-8.
-
(2014)
J Biol Chem
, vol.289
, pp. 30880-30888
-
-
Cole, S.P.C.1
-
15
-
-
0345688604
-
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
-
Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
-
(2003)
Oncogene
, vol.22
, pp. 7340-7358
-
-
Doyle, L.A.1
Ross, D.D.2
-
16
-
-
0033429542
-
Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells
-
Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59:5938-46.
-
(1999)
Cancer Res
, vol.59
, pp. 5938-5946
-
-
Brangi, M.1
Litman, T.2
Ciotti, M.3
Nishiyama, K.4
Kohlhagen, G.5
Takimoto, C.6
-
17
-
-
0034817098
-
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer
-
Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer. Biochem Biophys Res Commun 2001;280:1216-23.
-
(2001)
Biochem Biophys Res Commun
, vol.280
, pp. 1216-1223
-
-
Kawabata, S.1
Oka, M.2
Shiozawa, K.3
Tsukamoto, K.4
Nakatomi, K.5
Soda, H.6
-
18
-
-
20444393495
-
Tyrosine kinase inhibitor resistance in cancer: Role of ABC multidrug transporters
-
Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Updat 2005;8:15-26.
-
(2005)
Drug Resist Updat
, vol.8
, pp. 15-26
-
-
Ozvegy-Laczka, C.1
Cserepes, J.2
Elkind, N.B.3
Sarkadi, B.4
-
19
-
-
0026353317
-
Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporine A
-
Twentyman PR,Bleehan NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporine A. Eur J Cancer 1991;27:1639-42.
-
(1991)
Eur J Cancer
, vol.27
, pp. 1639-1642
-
-
Twentyman, P.R.1
Bleehan, N.M.2
-
20
-
-
77950224905
-
Antibody-maytansinoid conjugates designed to bypass multidrug resistance
-
Kovton YV, Audetta CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70:2528-37.
-
(2010)
Cancer Res
, vol.70
, pp. 2528-2537
-
-
Kovton, Y.V.1
Audetta, C.A.2
Mayo, M.F.3
Jones, G.E.4
Doherty, H.5
Maloney, E.K.6
-
21
-
-
84904756151
-
Glutathione S-conjugates as prodrugs to target drugresistant tumors
-
Ramsay EE, Dilda PJ. Glutathione S-conjugates as prodrugs to target drugresistant tumors. Front Pharmacol 2014;5:181.
-
(2014)
Front Pharmacol
, vol.5
, pp. 181
-
-
Ramsay, E.E.1
Dilda, P.J.2
-
22
-
-
79956008677
-
Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: Preclinical studies in human cancer xenograft models and monkeys
-
Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011;17:3157-69.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 3157-3169
-
-
Cardillo, T.M.1
Govindan, S.V.2
Sharkey, R.M.3
Trisal, P.4
Goldenberg, D.M.5
-
23
-
-
84930199314
-
Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibodydrug conjugate: Characterization and efficacy in pancreatic, gastric, and other cancers
-
Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibodydrug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem 2015;26:919-31.
-
(2015)
Bioconjug Chem
, vol.26
, pp. 919-931
-
-
Cardillo, T.M.1
Govindan, S.V.2
Sharkey, R.M.3
Trisal, P.4
Arrojo, R.5
Liu, D.6
-
24
-
-
84941253818
-
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
-
Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 2015;6: 22496-512.
-
(2015)
Oncotarget
, vol.6
, pp. 22496-22512
-
-
Goldenberg, D.M.1
Cardillo, T.M.2
Govindan, S.V.3
Rossi, E.A.4
Sharkey, R.M.5
-
25
-
-
84930220109
-
First in human trial of a novel anti-Trop-2-antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors
-
Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr, Vahdat LT, et al. First in human trial of a novel anti-Trop-2-antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res 2015;21:3870-8.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 3870-3878
-
-
Starodub, A.N.1
Ocean, A.J.2
Shah, M.A.3
Guarino, M.J.4
Picozzi, V.J.5
Vahdat, L.T.6
-
26
-
-
84951801438
-
Sacitumumab govitecan, a novel antibody drug conjugate, in patients with metastatic, platinum-resistant urothelial carcinoma
-
Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, et al. Sacitumumab govitecan, a novel antibody drug conjugate, in patients with metastatic, platinum-resistant urothelial carcinoma. Clin Genitourin Cancer 2016;14:e75-9.
-
(2016)
Clin Genitourin Cancer
, vol.14
, pp. e75-e79
-
-
Faltas, B.1
Goldenberg, D.M.2
Ocean, A.J.3
Govindan, S.V.4
Wilhelm, F.5
Sharkey, R.M.6
-
27
-
-
1242293677
-
Pheophorbide a is a specific probe for ABCG2 function and inhibition
-
Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 2004;64:1242-6.
-
(2004)
Cancer Res
, vol.64
, pp. 1242-1246
-
-
Robey, R.W.1
Steadman, K.2
Polgar, O.3
Morisaki, K.4
Blayney, M.5
Mistry, P.6
-
28
-
-
0037079708
-
The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors
-
Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002;99:507-12.
-
(2002)
Blood
, vol.99
, pp. 507-512
-
-
Scharenberg, C.W.1
Harkey, M.A.2
Torok-Storb, B.3
-
29
-
-
0028915934
-
Generation of a drug resistance profile by quantitation of mdr-1/P-Glycoprotein in the cell lines of the National Cancer Insitute anticancer drug screen
-
Alvarez M, Paull K, Monks A, Hose C, Lee J-S, Weinstein J, et al. Generation of a drug resistance profile by quantitation of mdr-1/P-Glycoprotein in the cell lines of the National Cancer Insitute anticancer drug screen. J Clin Invest 1995;95:2205-14.
-
(1995)
J Clin Invest
, vol.95
, pp. 2205-2214
-
-
Alvarez, M.1
Paull, K.2
Monks, A.3
Hose, C.4
Lee, J.-S.5
Weinstein, J.6
-
30
-
-
0032489520
-
DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139
-
Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
-
(1998)
J Biol Chem
, vol.273
, pp. 5858-5868
-
-
Rogakou, E.P.1
Pilch, D.R.2
Orr, A.H.3
Ivanova, V.S.4
Bonner, W.M.5
-
31
-
-
0000890967
-
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C
-
Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002;1:417-25.
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 417-425
-
-
Allen, J.D.1
Van Loevezijn, A.2
Lakhai, J.M.3
Van Der Valk, M.4
Van Tellingen, O.5
Reid, G.6
-
32
-
-
79960144930
-
Novel acrylonitrile derivatives, YHO-13371 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo
-
Yamazaki R, Nishiyama Y, Furuta T, Hatano H, Igarashi Y, Asakawa N, et al. Novel acrylonitrile derivatives, YHO-13371 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther 2011;10:1252-63.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 1252-1263
-
-
Yamazaki, R.1
Nishiyama, Y.2
Furuta, T.3
Hatano, H.4
Igarashi, Y.5
Asakawa, N.6
-
33
-
-
0033966957
-
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein
-
Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberg LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000;60:47-50.
-
(2000)
Cancer Res
, vol.60
, pp. 47-50
-
-
Rabindran, S.K.1
Ross, D.D.2
Doyle, L.A.3
Yang, W.4
Greenberg, L.M.5
-
34
-
-
16844377759
-
Cyclosporin A is a broad-spectrum multidrug resistance modulators
-
Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, et al. Cyclosporin A is a broad-spectrum multidrug resistance modulators. Clin Cancer Res 2005;11:2320-6.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 2320-2326
-
-
Qadir, M.1
O'Loughlin, K.L.2
Fricke, S.M.3
Williamson, N.A.4
Greco, W.R.5
Minderman, H.6
-
35
-
-
0032695270
-
Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
-
de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 1999;146:117-26.
-
(1999)
Cancer Lett
, vol.146
, pp. 117-126
-
-
De Bruin, M.1
Miyake, K.2
Litman, T.3
Robey, R.4
Bates, S.E.5
-
36
-
-
84941554175
-
The inhibitor Kp143 is not specific for ABCG2
-
Weidner LD, Zoghbi SS, Lu S, Shukla S, Ambudkar SV, Pike VW, et al. The inhibitor Kp143 is not specific for ABCG2. J Pharmacol Exp Ther 2015; 354:384-93.
-
(2015)
J Pharmacol Exp Ther
, vol.354
, pp. 384-393
-
-
Weidner, L.D.1
Zoghbi, S.S.2
Lu, S.3
Shukla, S.4
Ambudkar, S.V.5
Pike, V.W.6
-
37
-
-
84941222227
-
Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan)
-
Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res 2015;21:5131-8.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 5131-5138
-
-
Sharkey, R.M.1
McBride, W.J.2
Cardillo, T.M.3
Govindan, S.V.4
Wang, Y.5
Rossi, E.A.6
-
38
-
-
84873053339
-
Antibody-drug conjugates in cancer therapy
-
Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013;64:15-29.
-
(2013)
Annu Rev Med
, vol.64
, pp. 15-29
-
-
Sievers, E.L.1
Senter, P.D.2
-
39
-
-
84947770168
-
Field guides to challenges and opportunities in antibody-drug conjugates for chemists
-
Gordon MR, Canakci M, Li L, Zhuang J, Osborne B, Thayumanavan S. Field guides to challenges and opportunities in antibody-drug conjugates for chemists. Bioconjug Chem 2015;26:2198-215.
-
(2015)
Bioconjug Chem
, vol.26
, pp. 2198-2215
-
-
Gordon, M.R.1
Canakci, M.2
Li, L.3
Zhuang, J.4
Osborne, B.5
Thayumanavan, S.6
-
40
-
-
84985971613
-
Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC [abstract]
-
2015 Dec 8-12; San Antonio, TX. Philadelphia, PA: AACR Abstract nr PD3-06
-
Bardia A, Diamond JR, Mayer IA, Starodub AN, Moroose RL, Isakoff SJ, et al. Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC [abstract]. In: Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2015 Dec 8-12; San Antonio, TX. Philadelphia, PA: AACR; 2015. Abstract nr PD3-06.
-
(2015)
Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium
-
-
Bardia, A.1
Diamond, J.R.2
Mayer, I.A.3
Starodub, A.N.4
Moroose, R.L.5
Isakoff, S.J.6
-
41
-
-
6344237103
-
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecantreated metastases
-
Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecantreated metastases. Int J Cancer 2004;109:848-54.
-
(2004)
Int J Cancer
, vol.109
, pp. 848-854
-
-
Candeil, L.1
Gourdier, I.2
Peyron, D.3
Vezzio, N.4
Copois, V.5
Bibeau, F.6
-
42
-
-
84985984520
-
The activated MEK/ERK pathway may potentiate breast cancer resistance protein/ABCG2 function in SN38-selected MCF-7 cells
-
Imai Y, Ohmori K, Fukuda K, Ueda Y. The activated MEK/ERK pathway may potentiate breast cancer resistance protein/ABCG2 function in SN38-selected MCF-7 cells. JSM Clin Oncol Res 2014;2:1008.
-
(2014)
JSM Clin Oncol Res
, vol.2
, pp. 1008
-
-
Imai, Y.1
Ohmori, K.2
Fukuda, K.3
Ueda, Y.4
-
43
-
-
84960128193
-
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines
-
Jandu H, Aluzaite K, Fogh L, Thrane SW, Nohr JB, Proszek J, et al. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer 2016;16:34.
-
(2016)
BMC Cancer
, vol.16
, pp. 34
-
-
Jandu, H.1
Aluzaite, K.2
Fogh, L.3
Thrane, S.W.4
Nohr, J.B.5
Proszek, J.6
-
44
-
-
33645958870
-
Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer
-
Bessho Y, Oguri T, Achiwa H, Muramatsu H, Maeda H, Niimi T, et al. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. Cancer Sci 2006;97:192-8.
-
(2006)
Cancer Sci
, vol.97
, pp. 192-198
-
-
Bessho, Y.1
Oguri, T.2
Achiwa, H.3
Muramatsu, H.4
Maeda, H.5
Niimi, T.6
-
45
-
-
63449094928
-
Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride
-
Takara K, Kitada N, Yoshikawa E, Yamamoto K, Horibe H, Sakaeda T, et al. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Lett 2009; 278:88-96.
-
(2009)
Cancer Lett
, vol.278
, pp. 88-96
-
-
Takara, K.1
Kitada, N.2
Yoshikawa, E.3
Yamamoto, K.4
Horibe, H.5
Sakaeda, T.6
-
46
-
-
0035266161
-
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell lines
-
Urasaki Y, Laco GS, Pourquire P, Takebayashi Y, Kohlhagen G, Gioffre G, et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell lines. Cancer Res 2001; 61:1964-9.
-
(2001)
Cancer Res
, vol.61
, pp. 1964-1969
-
-
Urasaki, Y.1
Laco, G.S.2
Pourquire, P.3
Takebayashi, Y.4
Kohlhagen, G.5
Gioffre, G.6
-
47
-
-
85008600545
-
Characterization of DNA topoisomerase I in three SN-38 resistant human cancer cell lines reveals a new pair of resistance-associated mutations
-
Jensen NF, Agama K, Roy A, Smith DH, Pfister TD, Romer MU, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human cancer cell lines reveals a new pair of resistance-associated mutations. J Exp Clin Cancer Res 2016;35:56.
-
(2016)
J Exp Clin Cancer Res
, vol.35
, pp. 56
-
-
Jensen, N.F.1
Agama, K.2
Roy, A.3
Smith, D.H.4
Pfister, T.D.5
Romer, M.U.6
-
48
-
-
84867390244
-
Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase inhibitors
-
Tomicic MT, Kaina B. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase inhibitors. Biochim Biophys Acta 2013;1835:11-27.
-
(2013)
Biochim Biophys Acta
, vol.1835
, pp. 11-27
-
-
Tomicic, M.T.1
Kaina, B.2
-
49
-
-
0028145748
-
Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes?
-
Kerbel RS, Kobayashi H, Graham CH. Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem 1994;56:37-47.
-
(1994)
J Cell Biochem
, vol.56
, pp. 37-47
-
-
Kerbel, R.S.1
Kobayashi, H.2
Graham, C.H.3
-
50
-
-
84907101179
-
Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance
-
Anreddy N, Gupta P, Kathawala RJ, Patel A, Wurpel JND, Chen Z-S. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. Molecules 2014;19:13848-77.
-
(2014)
Molecules
, vol.19
, pp. 13848-13877
-
-
Anreddy, N.1
Gupta, P.2
Kathawala, R.J.3
Patel, A.4
Wurpel, J.N.D.5
Chen, Z.-S.6
|